Cargando…

Isocitrate dehydrogenase mutation is frequently observed in giant cell tumor of bone

Giant cell tumors of bone (GCTB) are benign and locally destructive tumors that include osteoclast-type multinuclear giant cells. No available treatment is definitively effective in curing GCTB, especially in surgically unresectable cases. Isocitrate dehydrogenase (IDH) mutations have been reported...

Descripción completa

Detalles Bibliográficos
Autores principales: Kato Kaneko, Mika, Liu, Xing, Oki, Hiroharu, Ogasawara, Satoshi, Nakamura, Takuro, Saidoh, Noriko, Tsujimoto, Yuta, Matsuyama, Yuka, Uruno, Akira, Sugawara, Masato, Tsuchiya, Takashi, Yamakawa, Mitsunori, Yamamoto, Masayuki, Takagi, Michiaki, Kato, Yukinari
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BlackWell Publishing Ltd 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4317903/
https://www.ncbi.nlm.nih.gov/pubmed/24898068
http://dx.doi.org/10.1111/cas.12413
_version_ 1782355755138023424
author Kato Kaneko, Mika
Liu, Xing
Oki, Hiroharu
Ogasawara, Satoshi
Nakamura, Takuro
Saidoh, Noriko
Tsujimoto, Yuta
Matsuyama, Yuka
Uruno, Akira
Sugawara, Masato
Tsuchiya, Takashi
Yamakawa, Mitsunori
Yamamoto, Masayuki
Takagi, Michiaki
Kato, Yukinari
author_facet Kato Kaneko, Mika
Liu, Xing
Oki, Hiroharu
Ogasawara, Satoshi
Nakamura, Takuro
Saidoh, Noriko
Tsujimoto, Yuta
Matsuyama, Yuka
Uruno, Akira
Sugawara, Masato
Tsuchiya, Takashi
Yamakawa, Mitsunori
Yamamoto, Masayuki
Takagi, Michiaki
Kato, Yukinari
author_sort Kato Kaneko, Mika
collection PubMed
description Giant cell tumors of bone (GCTB) are benign and locally destructive tumors that include osteoclast-type multinuclear giant cells. No available treatment is definitively effective in curing GCTB, especially in surgically unresectable cases. Isocitrate dehydrogenase (IDH) mutations have been reported not only in gliomas and acute myeloid leukemias, but also in cartilaginous tumors and osteosarcomas. However, IDH mutations in GCTB have not been investigated. The IDH mutations are remarkably specific to arginine 132 (R132) in IDH1 and arginine 172 (R172) or arginine 140 (R140) in IDH2; IDH1/2 mutations are known to convert α-ketoglutarate to oncometabolite R(-)-2-hydroxyglutarate. We recently reported that the most frequent IDH mutation in osteosarcomas is IDH2-R172S, which was detected by MsMab-1, a multispecific anti-IDH1/2 mAb. Herein, we newly report the IDH mutations in GCTB, which were stained by MsMab-1 in immunohistochemistry. DNA direct sequencing and subcloning identified IDH mutations of GCTB as IDH2-R172S (16 of 20; 80%). This is the first report to describe IDH mutations in GCTB, and MsMab-1 can be anticipated for use in immunohistochemical determination of IDH1/2 mutation-bearing GCTB.
format Online
Article
Text
id pubmed-4317903
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher BlackWell Publishing Ltd
record_format MEDLINE/PubMed
spelling pubmed-43179032015-10-05 Isocitrate dehydrogenase mutation is frequently observed in giant cell tumor of bone Kato Kaneko, Mika Liu, Xing Oki, Hiroharu Ogasawara, Satoshi Nakamura, Takuro Saidoh, Noriko Tsujimoto, Yuta Matsuyama, Yuka Uruno, Akira Sugawara, Masato Tsuchiya, Takashi Yamakawa, Mitsunori Yamamoto, Masayuki Takagi, Michiaki Kato, Yukinari Cancer Sci Report Giant cell tumors of bone (GCTB) are benign and locally destructive tumors that include osteoclast-type multinuclear giant cells. No available treatment is definitively effective in curing GCTB, especially in surgically unresectable cases. Isocitrate dehydrogenase (IDH) mutations have been reported not only in gliomas and acute myeloid leukemias, but also in cartilaginous tumors and osteosarcomas. However, IDH mutations in GCTB have not been investigated. The IDH mutations are remarkably specific to arginine 132 (R132) in IDH1 and arginine 172 (R172) or arginine 140 (R140) in IDH2; IDH1/2 mutations are known to convert α-ketoglutarate to oncometabolite R(-)-2-hydroxyglutarate. We recently reported that the most frequent IDH mutation in osteosarcomas is IDH2-R172S, which was detected by MsMab-1, a multispecific anti-IDH1/2 mAb. Herein, we newly report the IDH mutations in GCTB, which were stained by MsMab-1 in immunohistochemistry. DNA direct sequencing and subcloning identified IDH mutations of GCTB as IDH2-R172S (16 of 20; 80%). This is the first report to describe IDH mutations in GCTB, and MsMab-1 can be anticipated for use in immunohistochemical determination of IDH1/2 mutation-bearing GCTB. BlackWell Publishing Ltd 2014-06 2014-06-04 /pmc/articles/PMC4317903/ /pubmed/24898068 http://dx.doi.org/10.1111/cas.12413 Text en © 2014 The Authors. Cancer Science published by Wiley Publishing Asia Pty Ltd on behalf of Japanese Cancer Association. http://creativecommons.org/licenses/by-nc/3.0/ This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is noncommercial and no modifications or adaptations are made.
spellingShingle Report
Kato Kaneko, Mika
Liu, Xing
Oki, Hiroharu
Ogasawara, Satoshi
Nakamura, Takuro
Saidoh, Noriko
Tsujimoto, Yuta
Matsuyama, Yuka
Uruno, Akira
Sugawara, Masato
Tsuchiya, Takashi
Yamakawa, Mitsunori
Yamamoto, Masayuki
Takagi, Michiaki
Kato, Yukinari
Isocitrate dehydrogenase mutation is frequently observed in giant cell tumor of bone
title Isocitrate dehydrogenase mutation is frequently observed in giant cell tumor of bone
title_full Isocitrate dehydrogenase mutation is frequently observed in giant cell tumor of bone
title_fullStr Isocitrate dehydrogenase mutation is frequently observed in giant cell tumor of bone
title_full_unstemmed Isocitrate dehydrogenase mutation is frequently observed in giant cell tumor of bone
title_short Isocitrate dehydrogenase mutation is frequently observed in giant cell tumor of bone
title_sort isocitrate dehydrogenase mutation is frequently observed in giant cell tumor of bone
topic Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4317903/
https://www.ncbi.nlm.nih.gov/pubmed/24898068
http://dx.doi.org/10.1111/cas.12413
work_keys_str_mv AT katokanekomika isocitratedehydrogenasemutationisfrequentlyobservedingiantcelltumorofbone
AT liuxing isocitratedehydrogenasemutationisfrequentlyobservedingiantcelltumorofbone
AT okihiroharu isocitratedehydrogenasemutationisfrequentlyobservedingiantcelltumorofbone
AT ogasawarasatoshi isocitratedehydrogenasemutationisfrequentlyobservedingiantcelltumorofbone
AT nakamuratakuro isocitratedehydrogenasemutationisfrequentlyobservedingiantcelltumorofbone
AT saidohnoriko isocitratedehydrogenasemutationisfrequentlyobservedingiantcelltumorofbone
AT tsujimotoyuta isocitratedehydrogenasemutationisfrequentlyobservedingiantcelltumorofbone
AT matsuyamayuka isocitratedehydrogenasemutationisfrequentlyobservedingiantcelltumorofbone
AT urunoakira isocitratedehydrogenasemutationisfrequentlyobservedingiantcelltumorofbone
AT sugawaramasato isocitratedehydrogenasemutationisfrequentlyobservedingiantcelltumorofbone
AT tsuchiyatakashi isocitratedehydrogenasemutationisfrequentlyobservedingiantcelltumorofbone
AT yamakawamitsunori isocitratedehydrogenasemutationisfrequentlyobservedingiantcelltumorofbone
AT yamamotomasayuki isocitratedehydrogenasemutationisfrequentlyobservedingiantcelltumorofbone
AT takagimichiaki isocitratedehydrogenasemutationisfrequentlyobservedingiantcelltumorofbone
AT katoyukinari isocitratedehydrogenasemutationisfrequentlyobservedingiantcelltumorofbone